ST Pharm
CompanySouth Korea
ST Pharm develops one asset, in phase 2 (STP0404 in HIV-1 infection). Mostly small molecule; based in South Korea.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 1
- Signal
Pipeline
1Allosterically inhibits HIV-1 integrase, disrupting viral maturation and replication.
Phase 2, Small molecule, HIV-1 infection
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Signals1
- Similar companies2